OncoMatch/Clinical Trials/NCT05968768
To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly)
Is NCT05968768 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Naxitamab for ewing sarcoma.
Treatment: Naxitamab — Prospective, interventional, open, randomized, national, multicenter, non-commercial trial
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Sarcoma
Biomarker criteria
Required: GD2 positive expression (positive)
GD2 positive tumor assessed by IHC
Demographics
Prior therapy
Must have received: systemic anticancer treatment
Documented disease progression (during or after completion of at least one line treatment) or any subsequent recurrence.
Cannot have received: anti-GD2 antibody
Previous treatment with an anti-GD2 antibody.
Lab requirements
Cardiac function
Significant cardiac conduction abnormalities, including known familial prolonged QT syndrome, or screening corrected QT interval (QTc) >480 msec. Symptoms of congestive heart failure or left ventricular ejection fraction <50%.
Significant cardiac conduction abnormalities, including known familial prolonged QT syndrome, or screening corrected QT interval (QTc) >480 msec. Symptoms of congestive heart failure or left ventricular ejection fraction <50%.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05968768 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-GD2 antibody disqualifies patients from enrollment.
Does this trial require GD2?
Yes, GD2 positive expression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 21 years or younger and at least 2 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages